UK biotechnology spin-out developing targeted AAV gene therapies for focal refractory epilepsy; lead program EPY201 is delivered locally to seizure foci to reduce overactive neurons and aims to advance into Phase 1/2a clinical trials.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €33 M | Dec, 2025 | series-a |
Industries
Frequently Asked Questions
What industries does EpilepsyGTx operate in?
EpilepsyGTx operates in the following industries: biotechnology, gene therapy, healthcare, neurology.
How much total funding has EpilepsyGTx raised?
EpilepsyGTx has raised a total of $33,000,000.
Who are the investors in EpilepsyGTx?
The investors in EpilepsyGTx are: XGEN Venture, British Business Bank, Global biopharmaceutical company.